GPR55, a G-Protein Coupled Receptor for Lysophosphatidylinositol, Plays a Role in Motor Coordination

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Wu, Chia Shan ^a   Chen, Hongmei ^a   Sun, Hao ^a   Zhu, Jie ^a   Jew, Chris P ^a   Wager Miller, James ^b   Straiker, Alex ^b   Spencer, Corinne ^a   Bradshaw, Heather ^b   Mackie, Ken ^b   Lu, Hui Chen ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; GLUTAMATE RECEPTOR 2; LYSOPHOSPHATIDYLINOSITOL; MESSENGER RNA; NEURON SPECIFIC NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN CORTEX; CALCIUM CELL LEVEL; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DELETION MUTANT; DEPRESSION; FEMALE; FOREBRAIN; GENE EXPRESSION; GENOTYPE; HIPPOCAMPAL CA1 REGION; KNOCKOUT MOUSE; LEARNING; LONG TERM POTENTIATION; MALE; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; MUSCLE STRENGTH; NERVE CELL PLASTICITY; NEUROPHYSIOLOGY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIMARY SOMATOSENSORY CORTEX; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PYRAMIDAL NERVE CELL; SENSORIMOTOR FUNCTION; SENSORY DYSFUNCTION; SENSORY GATING; SEX DIFFERENCE;

ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM; CONDITIONING (PSYCHOLOGY); ENDOCANNABINOIDS; FEMALE; HIPPOCAMPUS; LYSOPHOSPHOLIPIDS; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; NEURONAL PLASTICITY; NEURONS; PSYCHOMOTOR PERFORMANCE; RECEPTORS, CANNABINOID; SYNAPSES;

MUS;

EID: 84875664752     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060314     Document Type: Article

References (68)

1. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, et al. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol Rev 62: 588-631.
2. Brown A, Wise A. (2003) Identification of modulators of GPR55 activity. In: Patent U, editor. USA: GlaxoSmithKline.
3. Drmota T, Greasley P., Groblewski T. (2004) Screening assays for cannabinoid-ligand-type modulators of GPR55. In: WIPO, editor. USA: AstraZeneca.
4. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, et al. (2007) The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152: 825-831.
5. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, et al. (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101.
6. Sharir H, Abood ME, (2010) Pharmacological characterization of GPR55, a putative cannabinoid receptor. Pharmacol Ther 126: 301-313.
7. Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T, (2007) Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 362: 928-934.
8. Henstridge CM, (2012) Off-target cannabinoid effects mediated by GPR55. Pharmacology 89: 179-187.
9. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, et al. (2008) GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105: 2699-2704.
10. Henstridge CM, Balenga NA, Schroder R, Kargl JK, Platzer W, et al. (2010) GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol 160: 604-614.
11. Staton PC, Hatcher JP, Walker DJ, Morrison AD, Shapland EM, et al. (2008) The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 139: 225-236.
12. Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, et al. (2009) The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A 106: 16511-16516.
13. Perez-Gomez E, Andradas C, Flores JM, Quintanilla M, Paramio JM, et al. (2012) The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas. Oncogene.
14. Romero-Zerbo SY, Rafacho A, Diaz-Arteaga A, Suarez J, Quesada I, et al. (2011) A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. J Endocrinol 211: 177-185.
15. Ross RA, (2011) L-alpha-lysophosphatidylinositol meets GPR55: a deadly relationship. Trends Pharmacol Sci 32: 265-269.
16. Kress M, Kuner R, (2009) Mode of action of cannabinoids on nociceptive nerve endings. Exp Brain Res 196: 79-88.
17. Idris AI, Ralston SH, (2010) Cannabinoids and bone: friend or foe? Calcif Tissue Int 87: 285-297.
18. Diaz-Arteaga A, Vazquez MJ, Vazquez-Martinez R, Pulido MR, Suarez J, et al. (2012) The atypical cannabinoid O-1602 stimulates food intake and adiposity in rats. Diabetes Obes Metab 14: 234-243.
19. Oesch S, Gertsch J, (2009) Cannabinoid receptor ligands as potential anticancer agents-high hopes for new therapies? J Pharm Pharmacol 61: 839-853.
20. Hu G, Ren G, Shi Y, (2011) The putative cannabinoid receptor GPR55 promotes cancer cell proliferation. Oncogene 30: 139-141.
21. Moreno-Navarrete JM, Catalan V, Whyte L, Diaz-Arteaga A, Vazquez-Martinez R, et al. (2012) The L-alpha-lysophosphatidylinositol/GPR55 system and its potential role in human obesity. Diabetes 61: 281-291.
22. Wu CS, Zhu J, Wager-Miller J, Wang S, O'Leary D, et al. (2010) Requirement of cannabinoid CB(1) receptors in cortical pyramidal neurons for appropriate development of corticothalamic and thalamocortical projections. Eur J Neurosci.
23. Bradshaw HB, Rimmerman N, Krey JF, Walker JM, (2006) Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators. Am J Physiol Regul Integr Comp Physiol 291: R349-358.
24. Straiker A, Mackie K, (2005) Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J Physiol 569: 501-517.
25. Chevaleyre V, Castillo PE, (2003) Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron 38: 461-472.
26. Crawley JN, Paylor R, (1997) A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm Behav 31: 197-211.
27. Paylor R, Crawley JN, (1997) Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology (Berl) 132: 169-180.
28. Paylor R, Nguyen M, Crawley JN, Patrick J, Beaudet A, et al. (1998) Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice. Learn Mem 5: 302-316.
29. Sawzdargo M, Nguyen T, Lee DK, Lynch KR, Cheng R, et al. (1999) Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res 64: 193-198.
30. Mackie K, Stella N, (2006) Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8: E298-306.
31. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, et al. (1998) An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353: 23-31.
32. Watanabe K, Matsunaga T, Nakamura S, Kimura T, Ho IK, et al. (1999) Pharmacological effects in mice of anandamide and its related fatty acid ethanolamides, and enhancement of cataleptogenic effect of anandamide by phenylmethylsulfonyl fluoride. Biol Pharm Bull 22: 366-370.
33. Bradshaw HB, Rimmerman N, Hu SS, Benton VM, Stuart JM, et al. (2009) The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways. BMC Biochem 10: 14.
34. McHugh D, Hu SS, Rimmerman N, Juknat A, Vogel Z, et al. (2010) N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci 11: 44.
35. Rimmerman N, Bradshaw HB, Hughes HV, Chen JS, Hu SS, et al. (2008) N-palmitoyl glycine, a novel endogenous lipid that acts as a modulator of calcium influx and nitric oxide production in sensory neurons. Mol Pharmacol 74: 213-224.
36. Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, et al. (2006) N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A 103: 2428-2433.
37. Smoum R, Bar A, Tan B, Milman G, Attar-Namdar M, et al. (2010) Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci U S A 107: 17710-17715.
38. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, et al. (2011) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334: 809-813.
39. Masserano JM, Weiner N, (1983) Tyrosine hydroxylase regulation in the central nervous system. Mol Cell Biochem 53-54: 129-152.
40. Blanchard V, Raisman-Vozari R, Vyas S, Michel PP, Javoy-Agid F, et al. (1994) Differential expression of tyrosine hydroxylase and membrane dopamine transporter genes in subpopulations of dopaminergic neurons of the rat mesencephalon. Brain Res Mol Brain Res 22: 29-38.
41. Tritto T, McCallum SE, Waddle SA, Hutton SR, Paylor R, et al. (2004) Null mutant analysis of responses to nicotine: deletion of beta2 nicotinic acetylcholine receptor subunit but not alpha7 subunit reduces sensitivity to nicotine-induced locomotor depression and hypothermia. Nicotine Tob Res 6: 145-158.
42. Peier AM, McIlwain KL, Kenneson A, Warren ST, Paylor R, et al. (2000) (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet 9: 1145-1159.
43. Mangieri RA, Piomelli D, (2007) Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. Pharmacol Res 56: 360-366.
44. Petit-Demouliere B, Chenu F, Bourin M, (2005) Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology (Berl) 177: 245-255.
45. Ito M (1984) The cerebellum and neural control. New York: Raven.
46. Houk JC, Wise SP, (1995) Distributed modular architectures linking basal ganglia, cerebellum, and cerebral cortex: their role in planning and controlling action. Cereb Cortex 5: 95-110.
47. Middleton FA, Strick PL, (2000) Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain Res Brain Res Rev 31: 236-250.
48. Kamens HM, Crabbe JC, (2007) The parallel rod floor test: a measure of ataxia in mice. Nat Protoc 2: 277-281.
49. Geyer MA, McIlwain KL, Paylor R, (2002) Mouse genetic models for prepulse inhibition: an early review. Mol Psychiatry 7: 1039-1053.
50. Phillips RG, LeDoux JE, (1992) Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav Neurosci 106: 274-285.
51. Safo PK, Cravatt BF, Regehr WG, (2006) Retrograde endocannabinoid signaling in the cerebellar cortex. Cerebellum 5: 134-145.
52. Kawamura Y, Fukaya M, Maejima T, Yoshida T, Miura E, et al. (2006) The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. J Neurosci 26: 2991-3001.
53. Kreitzer AC, Regehr WG, (2001) Cerebellar depolarization-induced suppression of inhibition is mediated by endogenous cannabinoids. J Neurosci 21: RC174.
54. Kreitzer AC, Regehr WG, (2001) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29: 717-727.
55. Maejima T, Hashimoto K, Yoshida T, Aiba A, Kano M, (2001) Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 31: 463-475.
56. Maejima T, Oka S, Hashimotodani Y, Ohno-Shosaku T, Aiba A, et al. (2005) Synaptically driven endocannabinoid release requires Ca2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase Cbeta4 signaling cascade in the cerebellum. J Neurosci 25: 6826-6835.
57. Yoshida T, Hashimoto K, Zimmer A, Maejima T, Araishi K, et al. (2002) The cannabinoid CB1 receptor mediates retrograde signals for depolarization-induced suppression of inhibition in cerebellar Purkinje cells. J Neurosci 22: 1690-1697.
58. Mackie K (2005) Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb Exp Pharmacol: 299-325.
59. Kishimoto Y, Kano M, (2006) Endogenous cannabinoid signaling through the CB1 receptor is essential for cerebellum-dependent discrete motor learning. J Neurosci 26: 8829-8837.
60. Dietz V, (2002) Proprioception and locomotor disorders. Nat Rev Neurosci 3: 781-790.
61. Hardisty-Hughes RE, Parker A, Brown SD, (2010) A hearing and vestibular phenotyping pipeline to identify mouse mutants with hearing impairment. Nat Protoc 5: 177-190.
62. Minasyan A, Keisala T, Zou J, Zhang Y, Toppila E, et al. (2009) Vestibular dysfunction in vitamin D receptor mutant mice. J Steroid Biochem Mol Biol 114: 161-166.
63. Pau H, Hawker K, Fuchs H, De Angelis MH, Steel KP, (2004) Characterization of a new mouse mutant, flouncer, with a balance defect and inner ear malformation. Otol Neurotol 25: 707-713.
64. Henstridge CM, Balenga NA, Kargl J, Andradas C, Brown AJ, et al. (2011) Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55. Mol Endocrinol 25: 1835-1848.
65. Neumann S, Doubell TP, Leslie T, Woolf CJ, (1996) Inflammatory pain hypersensitivity mediated by phenotypic switch in myelinated primary sensory neurons. Nature 384: 360-364.
66. Ruscheweyh R, Forsthuber L, Schoffnegger D, Sandkuhler J, (2007) Modification of classical neurochemical markers in identified primary afferent neurons with Abeta-, Adelta-, and C-fibers after chronic constriction injury in mice. J Comp Neurol 502: 325-336.
67. Jensen TP, Sylantyev S, Ross RA, Rusakov DA (2011) GPR55 modulates transmitter release and short term plasticity in the hippocampus by initiating store mediated pre-synaptic Ca2+ entry Neuroscience Meeting Planner Washington, DC: Society for Neuroscience Online: Program #448.408.
68. Sylantyev S, Jensen TP, Ross RA, Rusakov DA (2011) The enigmatic receptor GPR55 potentiates neurotransmitter release at central synapses. Neuroscience Meeting Planner Washington, DC: Society for Neuroscience Online: Program #653.601.